Saline Solution Basi 9 mg/ml solution for infusion
Sponsors
Region Hovedstaden, Algemeen Ziekenhuis Delta, Leids Universitair Medisch Centrum (LUMC), Universite De Liege, Centre Hospitalier Universitaire De Liege, Biogen Idec Research Limited
Conditions
Cannabis dependence (Cannabis Use Disorder or CUD)Disorder of ConsciousnessHealthy volunteers - no medical conditionKidney Transplant Recipients with Late Antibody-Mediated RejectionObesity and overweightTraumatic Brain InjuryTreatment of Late Isolated Microvascular Inflammation in Recipients of Kidney TransplantsUnipolar depression
Overweight and obesity
Phase 1
Imaging neural correlates of antidepressant action of ketamine stereoisomers using pharmacological PET/MR imaging and metabolite analysis.
RecruitingCTIS2024-519234-23-00
Start: 2020-01-17Target: 75Updated: 2025-01-30
Intraperitoneal treatment with fosfomycin, metronidazole and recombinant human granulocyte-macrophage colony-stimulating factor in patients with multi-quadrant peritonitis undergoing abdominal surgery: A randomized placebo-controlled trial (TRIPLE)
WithdrawnCTIS2024-520317-49-00
Target: 32Updated: 2025-06-12
Intraperitoneal treatment with fosfomycin, metronidazole and recombinant human granulocyte-macrophage colony-stimulating factor in patients with multi-quadrant peritonitis undergoing abdominal surgery: A randomized placebo-controlled trial (TRIPLE)
Not yet recruitingCTIS2024-520317-49-02
Target: 32Updated: 2026-01-12
Phase 2
(CIAO@TBI) Complement Inhibition: Attacking Overshooting Inflammation @fter traumatic brain injury
Not yet recruitingCTIS2024-514488-24-02
Target: 106Updated: 2026-01-23
Complexity-enhancing drugs to treat disorders of consciousness (DoC): a ketamine study
RecruitingCTIS2024-518433-29-00
Start: 2022-01-01Target: 40Updated: 2025-09-05
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI)- (299AR201-TRANSPIRE)
Not yet recruitingCTIS2025-521742-15-00
Target: 13Updated: 2026-02-10
A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder
Not yet recruitingCTIS2025-524163-21-00
Target: 100Updated: 2026-03-30
Phase 3
Is the glucagon-like peptide-1 receptor agonist semaglutide able to alleviate mood in patients with major depressive disorder and overweight or obesity? Sema-Mood.
RecruitingCTIS2024-511734-13-04
Start: 2025-05-15Target: 120Updated: 2025-12-23
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3
Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late
Antibody-Mediated Rejection (AMR) (TRANSCEND / 299AR301)
RecruitingCTIS2024-519095-66-00
Start: 2025-07-23Target: 49Updated: 2025-12-04